{
  "id": "doc:ema.elahere",
  "type": "Document",
  "documentType": "Regulatory approval",
  "name": "Elahere (mirvetuximab soravtansine) [product information]. EMA.",
  "title": null,
  "aliases": [],
  "description": "AbbVie Deutschland GmbH & Co. KG. Elahere (mirvetuximab soravtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf. Revised August 2025. Accessed September 8, 2025.",
  "urls": [
    "https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf",
    "https://www.ema.europa.eu/en/medicines/human/EPAR/elahere"
  ],
  "doi": null,
  "pmid": null,
  "extensions": [
    {
      "name": "agent",
      "value": {
        "id": "ema",
        "type": "Agent",
        "agentType": "organization",
        "name": "European Medicines Agency",
        "description": "Regulatory agency that approves medicines for use in the European Union.",
        "extensions": [
          {
            "name": "last_updated",
            "value": "2025-10-01",
            "description": ""
          },
          {
            "name": "url",
            "value": "https://www.ema.europa.eu/en/medicines",
            "description": ""
          }
        ]
      },
      "description": "The organization that published this document."
    },
    {
      "name": "application_number",
      "value": null,
      "description": "Biologic License Application (BLA) number, only applicable to documents from the US FDA."
    },
    {
      "name": "company",
      "value": "AbbVie Deutschland GmbH & Co. KG",
      "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
    },
    {
      "name": "drug_name_brand",
      "value": "Elahere",
      "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
    },
    {
      "name": "drug_name_generic",
      "value": "mirvetuximab soravtansine",
      "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
    },
    {
      "name": "first_publication_date",
      "value": "2024-12-10",
      "description": "The publication date for the initial version of this document."
    },
    {
      "name": "publication_date",
      "value": "2025-08-20",
      "description": "The publication date for the document."
    },
    {
      "name": "status",
      "value": "Active",
      "description": "Whether this document is Active or Deprecated within moalmanac-db."
    }
  ]
}